|
|
Volumn 30, Issue 10, 2012, Pages 906-907
|
|
Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI IGF 1R ANTIBODY A12;
ANTI-IGF-1R ANTIBODY A12;
ANTINEOPLASTIC AGENT;
FIGITUMUMAB;
GANITUMAB;
IMMUNOGLOBULIN;
MONOCLONAL ANTIBODY;
NEUTRALIZING ANTIBODY;
SOMATOMEDIN C;
SOMATOMEDIN C RECEPTOR;
CLINICAL TRIAL (TOPIC);
DRUG ANTAGONISM;
HUMAN;
METABOLISM;
NEOPLASM;
NOTE;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEUTRALIZING;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
HUMANS;
IMMUNOGLOBULINS, INTRAVENOUS;
INSULIN-LIKE GROWTH FACTOR I;
NEOPLASMS;
RECEPTOR, IGF TYPE 1;
|
|
EID: 84874441789
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1012-906c Document Type: Note |
|
Times cited : (20)
|
|
References (0)
|
